Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab

摘要: Ipilimumab, an antibody that blocks CTL antigen 4 (CTLA-4), improves overall survival (OS) for patients with metastatic melanoma. Given its role in angiogenesis and immune evasion, serum VEGF levels were evaluated association clinical benefit ipilimumab-treated patients. Sera collected from 176 treated at 3 (n = 98) or 10 mg/kg 68). The before treatment induction completion (week 12) analyzed using the Meso Scale Discovery kit. of responses OS assessed Fisher exact Kaplan-Meier log-rank tests. as a continuous variable was associated (P 0.002). Using 43 pg/mL cutoff pretreatment value defined by maximally selected statistics, values correlated week 24 0.019; 159 evaluable). Pretreatment ≥ decreased (median 6.6 vs. 12.9 months, P 0.006; 7.4 14.3 0.037 mg/kg; 6.2 10.9 0.048 mg/kg). There no correlation between changes outcome. Serum may be predictive biomarker ipilimumab is worthy prospective investigation various forms immunologic checkpoint blockade.